Discover why Vertex Pharmaceuticals outperforms amid biotech sector decline. Explore growth drivers, risks, and the ...

Key Points Alibaba is a Chinese AI stock that's dirt cheap. Meta Platforms is making a huge bet on AI that should pay off ...

Journavx is the first truly new painkiller approved by the Food and Drug Administration in more than 20 years. But the drug ...

News about Vertex Pharmaceuticals Inc., including commentary and archival articles published in The New York Times.

Whales with a lot of money to spend have taken a noticeably bearish stance on Vertex Pharmaceuticals. If we consider the specifics of each trade, it is accurate to state that 9% of the investors ...

Vertex Pharmaceuticals Incorporated remains a top Buy with a strong cystic fibrosis franchise, innovative pipeline, and cell therapies. Click for my VRTX update.

Investing at least part of the initial $1,000 in an artificial intelligence (AI) stock is a smart move. Despite impressive ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Detailed price information for Vertex Pharmaceutic (VRTX-Q) from The Globe and Mail including charting and trades.

Vertex Pharmaceuticals Inc. closed 10.71% below its 52-week high of $519.88, which the company reached on November 8th.

Buying $1000 In VRTX: If an investor had bought $1000 of VRTX stock 10 years ago, it would be worth $3,509.46 today based on a price of $459.81 for VRTX at the time of writing.

Vertex Pharmaceuticals Inc. closed 10.89% short of its 52-week high of $519.88, which the company achieved on November 8th.